𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy

✍ Scribed by Bernhard Zöllner; Peter Schäfer; Heinz-Hubert Feucht; Matthias Schröter; Jörg Petersen; Rainer Laufs

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
105 KB
Volume
65
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

It remains unclear whether sequential assessment of hepatitis B virus (HBV) load during lamivudine therapy can predict the loss of hepatitis B e antigen or emergence of drug‐resistant variants. Therefore, a longitudinal study was carried out in 28 consecutive patients with chronic hepatitis B who started lamivudine therapy for a median of 12 months (range, 6–31). HBV DNA copy numbers were determined at 3‐month intervals. From month 6 onward, HBV viral load below the detection limit of the PCR was predictive of the loss of envelope antigen (P = 0.043). Continuously detectable HBV DNA during the first 12 months of treatment indicated emergence of drug‐resistant variants (P = 0.034). These data suggest that the goal of lamivudine therapy should be complete suppression of serum HBV DNA. J. Med. Virol. 65:659–663, 2001. © 2001 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Mutational patterns of hepatitis B virus
Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: Analyses of the polymerase gene and full-length sequences
✍ Masaru Enomoto; Akihiro Tamori; Madoka Toyama Kohmoto; Hiroyasu Morikawa; Daiki 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB 👁 1 views

## Abstract It remains unclear whether mutational patterns of the hepatitis B virus (HBV) genome are associated with the development of severe hepatitis after the emergence of tyrosine‐methionine‐aspartate‐aspartate (YMDD) variants during lamivudine treatment. Thirty patients with chronic hepatitis

Evolution of viral load and changes of p
Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy
✍ U Im Chang; Young Chun Lee; Seong Heon Wie; Jeong Won Jang; Si Hyun Bae; Jong Yo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 1 views

## Abstract Adefovir dipivoxil (ADV) has demonstrated clinical activity against both wild‐type and lamivudine‐resistant hepatitis B virus (HBV). We analyzed the evolution of viral load and the changes of polymerase and precore/core promoter sequences in lamivudine‐resistant virus during ADV therapy